Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine to Collaborate with Charles River Labs

NEW YORK, May 13 - Charles River Laboratories International has signed an agreement to exclusively market and provide services for Rules-Based Medicine's Multi-Analyte Profiles (MAPS) for phenotypically characterizing laboratory research animals, the companies said today.


The MAP assay will "become our primary screening assay for viral antibody serology," said William Shek, senior technical director of Charles River's diagnostic and research services, in a statement.   The company will make reports of progress on these assays available to customers on its laboratory information management system


The MAP system includes 100 fluorescent microspheres dyed different colors, along with a bioassay, and a laser fluorescence detection system. On the beads are tests for plasma biomarkers including tissue-specific enzymes, hormones, cytokines, chemokines and acute-phase reactants. It is similar to the microsphere technology made by Luminex, of which Rules-Based Medicine is a spinoff.


The companies did not disclose the financial terms of the agreement. Charles River is based in Wilmington, Mass., and Rules-Based Medicine is based in Austin, Texas.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.